ID: ALA5267968

Max Phase: Preclinical

Molecular Formula: C21H19F4N5O3S2

Molecular Weight: 529.54

Associated Items:

Representations

Canonical SMILES:  CC(C)(C(=O)Nc1ccc(-c2cncc(C(F)(F)F)n2)cc1F)c1csc(NS(=O)(=O)C2CC2)n1

Standard InChI:  InChI=1S/C21H19F4N5O3S2/c1-20(2,17-10-34-19(29-17)30-35(32,33)12-4-5-12)18(31)28-14-6-3-11(7-13(14)22)15-8-26-9-16(27-15)21(23,24)25/h3,6-10,12H,4-5H2,1-2H3,(H,28,31)(H,29,30)

Standard InChI Key:  OKFGIMQRDHOBOP-UHFFFAOYSA-N

Associated Targets(Human)

CTP synthase 1 39 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Jurkat E6.1 134 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

CTP synthase 2 4 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

CTP synthase 2 4 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

CTP synthase 2 4 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

CTP synthase 1 4 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 529.54Molecular Weight (Monoisotopic): 529.0865AlogP: 4.58#Rotatable Bonds: 7
Polar Surface Area: 113.94Molecular Species: ACIDHBA: 7HBD: 2
#RO5 Violations: 1HBA (Lipinski): 8HBD (Lipinski): 2#RO5 Violations (Lipinski): 1
CX Acidic pKa: 6.47CX Basic pKa: 0.30CX LogP: 4.02CX LogD: 3.34
Aromatic Rings: 3Heavy Atoms: 35QED Weighted: 0.43Np Likeness Score: -1.74

References

1. Novak A, Laughton D, Lane R, Blackham E, Thomas J, Chatzopoulou E, Wrigglesworth J, Quddus A, Ahmed S, Cousin D, Duffy L, Dubois N, Unitt J, Orban K, Browne E, Ward M, Mycock D, Ieva M, Bland N, George P, Bourne T, Asnagli H, Birch L, Jones G..  (2022)  Discovery and Optimization of Potent and Orally Available CTP Synthetase Inhibitors for Use in Treatment of Diseases Driven by Aberrant Immune Cell Proliferation.,  65  (24.0): [PMID:36449304] [10.1021/acs.jmedchem.2c01446]

Source